Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants
Launched by UNIVERSITY OF OXFORD · May 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Baby-CINO trial is studying how changes in caffeine treatment affect the brain activity and breathing of premature infants. Caffeine is commonly given to these babies to help with their breathing. In this trial, researchers will monitor brain activity before and two days after adjusting the caffeine dose, while also keeping an eye on the babies' breathing, heart rate, and oxygen levels for up to two weeks.
To participate in this study, infants must be born prematurely (before 37 weeks of pregnancy), admitted to the Newborn Care Unit at John Radcliffe Hospital, and currently receiving caffeine treatment. A parent or guardian must provide written consent for their baby to join the trial. It’s important to note that babies with serious genetic issues or severe brain injuries will not be included. This study aims to provide valuable insights into how caffeine affects the health of premature infants, which could lead to better care for these vulnerable babies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Born to a mother aged 16 or over
- • Admitted to the Newborn Care Unit, John Radcliffe Hospital
- • Born prematurely (before 37 weeks' gestation)
- • Parent given informed written consent
- • Receiving caffeine citrate
- Exclusion Criteria:
- • Known chromosomal abnormality or life-threatening congenital abnormality
- • Severe hypoxic insult at birth
- • Intraventricular haemorrhage grade III or IV or other severe neurological pathology
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, Oxfordshire, United Kingdom
Patients applied
Trial Officials
Caroline Hartley
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported